Q3 FY26 results: revenue up 16 percent YoY, PAT jumps 26 percent
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.2 pts more than Nifty Microcap 250 and 2.8 pts more than its Retailing peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
MedPlus Health Services reported Q3 FY26 consolidated revenue from operations of Rs 18,061 million, up 15.7 percent YoY from Rs 15,614 million. Net profit after tax rose 26 percent YoY to Rs 578 million from Rs 459 million. Nine month revenue grew 8.7 percent to Rs 50,281 million with PAT up 57 percent at Rs 1,556 million. EPS for the quarter stood at Rs 4.82 versus Rs 3.84. Retail segment drove growth. Auditor B S R and Co gave an unmodified limited review opinion. Board also allotted 2,32,061 shares under ESOP 2021.
Strong profit growth signals margin expansion, likely positive for the stock. Minor ESOP dilution noted.